Volume 10, Number 3—March 2004
Dispatch
Immunofluorescence Assay for Serologic Diagnosis of SARS
Paul K.S. Chan*
, King-Cheung Ng*, Rickjason C. W. Chan*, Rebecca K. Y. Lam*, Viola C. Y. Chow*, Mamie Hui*, Alan Wu*, Nelson Lee*, Florence H.Y. Yap*, Frankie W. T. Cheng*, Joseph J. Y. Sung*, and John S. Tam*
, King-Cheung Ng*, Rickjason C. W. Chan*, Rebecca K. Y. Lam*, Viola C. Y. Chow*, Mamie Hui*, Alan Wu*, Nelson Lee*, Florence H.Y. Yap*, Frankie W. T. Cheng*, Joseph J. Y. Sung*, and John S. Tam*
Table
Anti-SARS-CoV IgG positive rate and titer according to time of blood sample collectiona
| Time of sample collection after onset of fever | No. of samples tested | No. (%) of samples with anti–SARS IgG antibody detected | Anti-SARS IgG antibody titer, range (mode) |
|---|---|---|---|
| 1–5 days |
64 |
0 |
– |
| 6–10 days |
35 |
12 (34.3) |
40–320 (160) |
| 11–15 days |
23 |
18 (78.3) |
40–640 (320) |
| 16–20 days |
43 |
42 (97.7) |
40–2,560 (640) |
| 21–37b days | 47 | 47 (100) | 80–5,120 (640) |
aSARS, severe acute respiratory syndrome; CoV, coronavirus; IgG, immunoglobulin G; –, not applicable.
bMedian collection time: 22 days; interquartile range: 4 days
Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.